Leukocyte interferon in patients with juvenile laryngeal papillomatosis.
Fourteen patients with aggressive juvenile papillomatosis were treated with systemic administration of alpha-type interferon (IFN). This initial dosage of 2 million units alpha-interferon/m2 was modified if a favorable response in the papilloma growth occurred, or if persistent drug-related side effects developed. Half of the patients showed a sustained response while on IFN, and two patients had a complete response. Persistent elevation in SGOT was the main dose-limiting toxicity, especially in infants below age seven years. All side effects subsided after the drug was discontinued. Further studies are recommended.
D000293:Adolescent; D000328:Adult; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D007822:Laryngeal Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D010212:Papilloma / Q000175:diagnosis / Q000188:drug therapy*; D011446:Prospective Studies
D007372:Interferons